MTOR and cancer: Additionally, several critical cancer-associated pathways showed significant depletion in the high-risk group, including allograft rejection (t = −4.03, adj.P.Val = 0.002), complement (t = −3.84, adj.P.Val = 0.002), and PI3K-AKT-MTOR signaling (t = −3.34, adj.P.Val = 0.006).